Metabolism and disposition of a potent and selective JNK inhibitor [14C]tanzisertib following oral administration to rats, dogs and humans
Authors:
- Matthew HoffmannMHMatthew Hoffmann
- Ying YeYYYing Ye
- Gondi KumarGKGondi Kumar
- Sekhar SurapaneniSSSekhar Surapaneni
- 21 November 2014
- journal article
- clinical trial
- Published by Taylor & Francis in Xenobiotica
- Vol. 45 (5) , 428-441
Abstract
1. The disposition of tanzisertib [(1S,4R)-4-(9-((S)tetrahydrofuran-3-yl)-8-(2,4,6-trifluorophenylamino)-9H-purin-2-ylamino) cyclohexanol], a potent, orally active c-Jun amino-terminal kinase inhibitor intended for treatment of fibrotic diseases was studied in rats, dogs and humans following a single oral dose of [(14)C]tanzisertib (Independent Investigational Review Board Inc., Plantation, FL). 2. Administered dose was quantitatively recovered in all species and feces/bile was the major route of elimination. Tanzisertib was rapidly absorbed (Tmax: 1-2 h) across all species with unchanged tanzisertib representing >83% of plasma radioactivity in dogs and humans, whereas <34% was observed in rats. Variable amounts of unchanged tanzisertib (1.5-32% of dose) was recovered in urine/feces across all species, the highest in human feces. 3. Metabolic profiling revealed that tanzisertib was primarily metabolized via oxidation and conjugation pathways, but extensively metabolized in rats relative to dogs/humans. CC-418424 (S-cis isomer of tanzisertib) was the major plasma metabolite in rats (38.4-46.4% of plasma radioactivity), while the predominant plasma metabolite in humans and dogs was M18 (tanzisertib-/CC-418424 glucuronide), representing 7.7 and 3.2% of plasma radioactivity, respectively. Prevalent biliary metabolite in rats and dogs, M18 represented 16.8 and 17.1% of dose, respectively. 4. In vitro studies using liver subcellular fractions and expressed enzymes characterized involvement of novel human aldo-keto reductases for oxido-reduction and UDP-glucuronosyltransferases for conjugation pathways.Keywords
This publication has 13 references indexed in Scilit:
- Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymesBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Discovery of CC-930, an orally active anti-fibrotic JNK inhibitorBioorganic & Medicinal Chemistry Letters, 2012
- Evaluation of JNK Blockade as an Early Intervention Treatment for Type 1 Diabetic Nephropathy in Hypertensive RatsAmerican Journal of Nephrology, 2011
- Increased ERK and JNK activities correlate with disease activity in patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2010
- c-Jun N-Terminal Kinase 1 Is Required for the Development of Pulmonary FibrosisAmerican Journal of Respiratory Cell and Molecular Biology, 2009
- A Pathogenic Role for c-Jun Amino-Terminal Kinase Signaling in Renal Fibrosis and Tubular Cell ApoptosisJournal of the American Society of Nephrology, 2007
- Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal KinasesMicrobiology and Molecular Biology Reviews, 2006
- Transforming Growth Factor- β1 Induces Phenotypic Modulation of Human Lung Fibroblasts to Myofibroblast Through a c-Jun-NH2-Terminal Kinase-Dependent PathwayAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Signal Transduction by the JNK Group of MAP KinasesCell, 2000
- Species variations in the threshold molecular-weight factor for the biliary excretion of organic anionsBiochemical Journal, 1972